(19)
(11) EP 2 070 920 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.04.2011 Bulletin 2011/17

(45) Mention of the grant of the patent:
02.03.2011 Bulletin 2011/09

(21) Application number: 09151443.0

(22) Date of filing: 24.07.1997
(51) International Patent Classification (IPC): 
C07D 401/04(2006.01)
 A61K 31/445(2006.01)

(54)

Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels

Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen

2-(2,6-dioxopipéridin-3-yl)-phtalimides et 1-oxoisoindolines substituées et procédé pour réduire les niveaux de TNF alpha

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 24.07.1996 US 690258
22.08.1996 US 701494
30.05.1997 US 48278 P

(43) Date of publication of application:
17.06.2009 Bulletin 2009/25

(60) Divisional application:
10183268.1 / 2305663

(62) Application number of the earlier application in accordance with Art. 76 EPC:
02012942.5 / 1285916
97936295.1 / 0925294

(73) Proprietor: CELGENE CORPORATION
Warren, NJ 07059 (US)

(72) Inventors:
  • Muller, George W
    Rancho Santa Fe, CA 92067 (US)
  • Stirling, David
    Branchburg, NJ 08876 (US)
  • Chen, Roger, Shen-Chu
    Edison, NJ 08820 (US)

(74) Representative: Hutter, Anton et al
Venner Shipley LLP 20 Little Britain
London EC1A 7DH
London EC1A 7DH (GB)


(56) References cited: : 
WO-A-98/03502
US-A- 5 635 517
 US-A- 5 463 063
   
  • NIWAYAMA S ET AL: "POTENT INHIBITION OF TUMOR NECROSIS FACTOR-ALPHA PRODUCTION BY TETRAFLUOROTHALIDOMIDE AND TETRAFLUOROPHTHALAMIDES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, vol. 39, no. 16, 1 January 1996 (1996-01-01), page 3044/3045, XP002048231 ISSN: 0022-2623
  • HE WEIXUAN ET AL: "Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease." ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 206, no. 1-2, 1993, page MEDI 216, XP009001980 206th ACS;Chicago, Illinois, USA; August 22-27, 1993 ISSN: 0065-7727
  • WNENDT ET AL: "Enantioselective inhibition of TNF-.alpha. release by thalidomide and thalidomide-analogs" CHIRALITY, WILEY-LISS, NEW YORK, US, vol. 8, 1996, pages 390-396, XP002074569 ISSN: 0899-0042
  • MIYACHI H ET AL: "Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: Influence of substituents at the phthaloyl moiety on the activity and stereoselectivity" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 46, no. 7, July 1998 (1998-07), pages 1165-1168, XP002107774 ISSN: 0009-2363
  • MULLER GEORGE W ET AL: "Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 11, 7 June 1999 (1999-06-07), pages 1625-1630, XP004169632 ISSN: 0960-894X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).